Aquestive Therapeutics (AQST) Releases Earnings Results, Misses Expectations By $0.10 EPS

Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.10), MarketWatch Earnings reports. The business had revenue of $12.64 million during the quarter, compared to analysts’ expectations of $10.66 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.

Shares of NASDAQ AQST opened at $3.72 on Friday. The company has a debt-to-equity ratio of 4.23, a current ratio of 1.89 and a quick ratio of 1.71. The firm has a market capitalization of $100.65 million and a P/E ratio of -1.33. Aquestive Therapeutics has a one year low of $3.65 and a one year high of $20.70.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Aquestive Therapeutics by 36.1% in the fourth quarter. BlackRock Inc. now owns 641,800 shares of the company’s stock valued at $4,042,000 after purchasing an additional 170,396 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Aquestive Therapeutics by 56.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 473,930 shares of the company’s stock worth $2,986,000 after purchasing an additional 170,984 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Aquestive Therapeutics by 83.8% during the fourth quarter. Perceptive Advisors LLC now owns 2,113,400 shares of the company’s stock worth $13,314,000 after purchasing an additional 963,400 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Aquestive Therapeutics by 245,514.3% during the fourth quarter. Bank of Montreal Can now owns 120,351 shares of the company’s stock worth $758,000 after purchasing an additional 120,302 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $188,000. Institutional investors and hedge funds own 57.75% of the company’s stock.

AQST has been the subject of several recent research reports. Wedbush set a $31.00 price target on Aquestive Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 8th. HC Wainwright started coverage on Aquestive Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $10.00 target price for the company. Zacks Investment Research raised Aquestive Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Thursday, March 21st. Lake Street Capital reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research report on Wednesday, February 20th. Finally, BMO Capital Markets cut their price target on Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Aquestive Therapeutics presently has a consensus rating of “Buy” and an average target price of $19.54.

ILLEGAL ACTIVITY WARNING: “Aquestive Therapeutics (AQST) Releases Earnings Results, Misses Expectations By $0.10 EPS” was originally reported by Rockland Register and is the sole property of of Rockland Register. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://rocklandregister.com/2019/06/01/aquestive-therapeutics-aqst-announces-earnings-results.html.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.